Longevity.Technology UNLOCKED

Epizode

• 
  Can Longevity Become Public Policy? 27.07.2026 48min

  Hosts:Phil Newman: ⁠https://qrco.de/bgXpNY⁠Nina Patrick: ⁠⁠⁠https://qrco.de/bgXpKn⁠----------Sponsor: FlexBeamFlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.Link: ⁠rechargehealthas.sjv.io/jRQyQ5⁠----------Guests: Dylan V. LivingstonFounder and CEO of The Alliance for Longevity Initiatives (A4LI)LinkedIn: ⁠www.linkedin.com/in/dylan-v-livingston/⁠Website: ⁠a4li.org/⁠----------What if the biggest barrier to longer, healthier lives isn't scientific discovery, but public policy?In this episode, Phil Newman and Dr. Nina Patrick sit down with Dylan V. Livingston, founder and CEO of the Alliance for Longevity Initiatives (A4LI), to explore how Washington is becoming one of the most important frontiers in healthy aging.Based on his unusual journey from political campaigning to longevity advocacy, Dylan explains why extending healthy lifespan requires more than innovative biotechnology. It also requires regulatory reform, stronger public investment, and policymakers who understand the biology of aging. From his work advancing state-level Right to Try legislation to proposals for new FDA pathways that recognize therapies targeting multiple age-related diseases, he shares how policy could dramatically accelerate the translation of longevity science into clinical practice.The conversation explores the growing role of biomarkers, surrogate endpoints, and ARPA-H's PROSPR program in creating clearer regulatory pathways for aging interventions. Dylan also discusses proposals for expanding NIH support for aging biology research, why the current funding landscape remains misaligned with the burden of age-related disease, and how advocacy organizations can help bridge the gap between researchers, biotech companies, regulators, and elected officials.They also examine whether the United States can maintain its leadership in longevity innovation as countries around the world invest in their own longevity ecosystems, and why creating the right incentives today could determine who leads the next generation of medicine.In this episode, you’ll learn:Why public policy may become the biggest accelerator, or bottleneck, for longevity science.How a proposed multi-disease therapeutic designation could speed the development of aging interventions.- Why validated biomarkers and surrogate endpoints are essential for future FDA approval pathways.How Right to Try legislation could expand safe access to experimental longevity therapies while generating valuable clinical data.Why stronger NIH investment, regulatory reform, and grassroots advocacy are all needed to bring longevity medicine into mainstream healthcare.If you want to understand how longevity is evolving from a scientific discipline into a healthcare and public policy movement, this episode explores the people, institutions, and regulatory decisions that could shape the future of healthy aging for decades to come.Subscribe for weekly conversations exploring longevity science, biotechnology, preventative medicine, and the innovations transforming how we live longer and better.
• 
  The First Real Longevity Drugs Are Getting Closer | Longevity News Roundup – Week 30, 2026 24.07.2026 28min

  Hosts:Phil Newman: https://qrco.de/bgXpNYNina Patrick: ⁠⁠https://qrco.de/bgXpKn----------Sponsor: FlexBeamFlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.Link: https://rechargehealthas.sjv.io/jRQyQ5----------In this week's Longevity News Roundup, Phil Newman and Nina Patrick examine major advances in Alzheimer's research, growing investment in national longevity infrastructure, the challenges facing longevity clinics, and why microbiome science is becoming increasingly important for brain and women's health.Biogen and Ionis reported encouraging Phase II results for a tau-targeting Alzheimer's therapy. While the trial missed its primary endpoint, the treatment reduced tau biomarkers and slowed clinical decline, supporting plans for a Phase III study.Lighthouse Pharmaceuticals presented new data showing its gingipain inhibitor reduced agitation, caregiver distress, and cognitive decline in Alzheimer's patients who tested positive for p. gingivalis. The discussion explores what these findings could mean for the growing evidence linking oral health and neurodegeneration.Nova Capital committed $100 million to build a UAE longevity platform integrating clinics, preventive healthcare, digital health, and wellness services. Phil also explores what this investment could signal for the future geography of the global longevity industry.Eternal announced the closure of its longevity clinics, prompting a discussion about why data, defensible technology, and scalable business models may become increasingly important as the sector matures.Juno Bio raised $3.8 million to launch a CLIA-certified sequencing laboratory and expand provider-led vaginal microbiome diagnostics, moving precision women's healthcare beyond traditional symptom-based testing.----------News & References:Biogen, Ionis therapy slows early Alzheimer’s progression in Phase 2 trial → https://longevity.technology/news/biogen-ionis-therapy-slows-early-alzheimers-progression-in-phase-2-trial/Lighthouse Pharma’s Alzheimer’s drug reduces agitation, caregiver distress in clinical trial → https://longevity.technology/news/lighthouse-pharmas-alzheimers-drug-reduces-agitation-caregiver-distress-in-clinical-trial/Nova Capital commits $100m to back UAE longevity platform → https://longevity.technology/news/nova-capital-commits-100m-to-back-uae-longevity-platform/Eternal calls time on its longevity clinics → https://longevity.technology/news/eternal-calls-time-on-its-longevity-clinics/Startup Juno Bio raises $3.8m for smarter women’s diagnostics → https://longevity.technology/news/startup-juno-bio-raises-3-8m-for-smarter-womens-diagnostics/
• 
  Are You Taking Too Many Supplements? Gut Health, Blood Tests & Personalized Longevity 20.07.2026 56min

  Hosts:Phil Newman: https://qrco.de/bgXpNYNina Patrick: ⁠⁠https://qrco.de/bgXpKn----------Sponsor: FlexBeamFlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.Link: rechargehealthas.sjv.io/jRQyQ5----------Guests: Aaron DeereHealth and Performance Director of HOOKE LondonLinkedIn: www.linkedin.com/in/aaron-deere-129079128/Website: www.hooke.london/Dr Jean-Marc SobczykIntegrative Medicine & Longevity Physician of HOOKE LondonLinkedIn: www.linkedin.com/in/jean-marc-sobczyk/Website: www.hooke.london/----------What if the future of longevity isn't about taking more supplements, but taking fewer, better ones?In this episode, Phil Newman and Dr. Nina Patrick are joined by HOOKE London experts Aaron Deere, Health and Performance Director, and Dr. Jean-Marc Sobczyk, an integrative longevity physician, to explore how personalized nutrition, biomarker testing, and gut health are reshaping the future of preventive healthcare.Drawing on years of clinical experience, they challenge the growing culture of "stacking" supplements without evidence, explaining why many people unknowingly oversupplement certain nutrients while remaining deficient in others. Through real-world case studies, they discuss why comprehensive blood testing should come before supplementation, how personalized formulations outperform generic multivitamins, and why regular monitoring is essential as your health, lifestyle, and physiology evolve over time.The conversation also explores one of the most exciting frontiers in longevity: the microbiome. Aaron and Dr. Sobczyk explain why gut health is far more complex than simply taking probiotics, why the same stool sample can produce completely different results when analyzed by different laboratories, and how emerging AI-powered research could unlock more targeted microbiome therapies for inflammation, cognitive health, mood, skin aging, and disease prevention.Throughout the conversation, one message remains clear: longevity isn't about chasing every new technology or buying every trending supplement. It's about understanding your unique biology and making informed decisions based on data, evidence, and continuous monitoring rather than marketing claims or social media advice.In this episode, you’ll learn:Why taking more supplements can increase the risk of nutrient overload and unnecessary expense.How blood biomarkers can uncover hidden deficiencies like iron, vitamin D, and omega-3 insufficiency while identifying oversupplementation. Why microbiome testing remains useful despite inconsistent laboratory results, and how to interpret those findings in clinical practice. How GLP-1 therapies can support healthspan when combined with strength training, adequate protein intake, and lifestyle change. Why sleep, nutrition, cardiovascular fitness, muscle health, and consistent monitoring still outperform the latest longevity trends.Whether you're building your first supplement protocol or refining an advanced longevity strategy, this conversation offers a practical framework for moving beyond guesswork and toward truly personalised health optimisation. It connects emerging science with real-world clinical experience, showing why testing, monitoring, and individualisation are becoming the new foundation of preventive medicine.Subscribe for weekly episodes exploring longevity science, precision medicine, preventative healthcare, and the innovations shaping how we live longer, healthier lives.
• 
  Is Longevity Becoming the Next Global Race? | Longevity News Roundup — Week 29, 2026 17.07.2026 30min

  Hosts:Phil Newman: https://qrco.de/bgXpNYNina Patrick: ⁠⁠https://qrco.de/bgXpKn----------Sponsor: FlexBeamFlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.Link: rechargehealthas.sjv.io/jRQyQ5----------In this week's Longevity News Roundup, Phil Newman and Nina Patrick examine BioAge's inflammation therapy, Alzheimer's advances, China's growing biotech influence, protein repair research, menopause science and US longevity policy.BioAge dosed the first patient in the Phase 2 QUELL-CV trial of BGE-102, an oral NLRP3 inflammasome inhibitor discovered through human longevity datasets rather than traditional disease-first drug discovery.Alzheon presented new analyses showing reduced brain swelling, preserved brain structure and encouraging biomarker and cognitive signals for valiltramiprosate, despite the original Phase 3 trial missing its primary endpoint. Confirmation studies are still needed.Kailera licensed its entire GLP-1 pipeline from China's Jiangsu Hengrui, highlighting growing US concerns over China's expanding role in drug innovation and obesity therapeutics.Revel Pharmaceuticals enzymatically removed advanced glycation end product (CML) damage from aged human tissues ex vivo, challenging long-held assumptions that some forms of molecular aging are irreversible.Elysium reported early pilot data suggesting its NAD+ supplement Basis reduced several menopause symptoms within seven days while also shifting estrogen metabolism biomarkers. Larger randomized trials are now needed.US policymakers and regulators outlined new frameworks supporting geotherapeutics, aging biomarkers and reimbursement, signalling growing federal momentum behind healthspan-focused medicine.----------News & References:BioAge doses first patient in Phase 2 trial of new cardiovascular drug → https://longevity.technology/news/bioage-doses-first-patient-in-phase-2-trial-of-new-cardiovascular-drug/Fresh analyses reshape Alzheon’s oral Alzheimer’s drug → https://longevity.technology/news/fresh-analyses-reshape-alzheons-oral-alzheimers-drug/Kailera’s oral obesity pill posts Phase 3 gains → https://longevity.technology/news/kaileras-oral-obesity-pill-posts-phase-3-gains/When irreversible no longer means forever → https://longevity.technology/news/when-irreversible-no-longer-means-forever/Elysium pilot study links Basis to reduced menopause symptoms → https://longevity.technology/news/elysium-pilot-study-links-basis-to-reduced-menopause-symptoms/US longevity policy takes center stage in Washington → https://longevity.technology/news/us-longevity-policy-takes-center-stage-in-washington/
• 
  The Genetic Clues That Could Predict How You Age 13.07.2026 40min

  Hosts:Phil Newman: https://qrco.de/bgXpNYNina Patrick: ⁠⁠https://qrco.de/bgXpKn----------Sponsor: FlexBeamFlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.Link: rechargehealthas.sjv.io/jRQyQ5----------Guests: Professor Ronjon Nag, OBEPresident of the R42 Group, CEO and Founder of Agemica and Board Advisor at Genomelink and YourRootsLinkedIn: www.linkedin.com/in/ronjonnag/Website: www.r42group.com/, agemica.com, app.superbio.ai, genomelink.io, yourroots.com----------What if your DNA and AI could become one of the most powerful tools for preventing disease, optimizing health, and extending healthy lifespan?Phil Newman and Dr. Nina Patrick sit down with Ronjon Nag, OBE, President of R42, CEO of Aegemica and Superbio.ai, and Adjunct Professor in Genetics at the Stanford School of Medicine, to explore how artificial intelligence is reshaping genomics and why we're entering a new era of personalized healthcare.Ronjon explains why most diseases are far more complex than single-gene mutations, and why understanding biology increasingly requires combining genetics with biomarkers, clinical records, lifestyle, and AI. He shares why genetics should be viewed as a lifelong health blueprint rather than a one-time report, and how future AI systems may allow people to interact with their own biology in entirely new ways.The conversation also explores why medicine is shifting toward prediction rather than reaction, how AI is helping researchers identify disease patterns hidden inside massive biological datasets, and why better data could dramatically accelerate drug discovery and preventative healthcare.Ronjon also discusses one of his boldest projects yet: developing peptide-based vaccines that target multiple aging pathways simultaneously. By combining AI with large-scale biological datasets, his team hopes to train the immune system to recognize and eliminate damaged cells before they contribute to age-related disease.In this episode, you’ll learn:Why most diseases are influenced by thousands of genes, not just oneHow AI is making genetics more useful for everyday healthcare Why combining genetics with biomarkers creates better health insights How preventative medicine is moving toward personalized risk prediction The science behind peptide vaccines targeting aging pathways Why AI may soon let you "talk" to your own biologyIf you're interested in AI, biotechnology, longevity science, and the future of healthcare, this episode offers an inside look at the technologies that could fundamentally change how we prevent disease and extend healthy lifespan.Subscribe for weekly conversations exploring longevity science, biotechnology, and the innovations helping people live healthier, longer lives.
• 
  Is Luxury Longevity Coming to an End? | Longevity News Roundup — Week 28, 2026 10.07.2026 26min

  Hosts:Phil Newman: https://qrco.de/bgXpNYNina Patrick: ⁠⁠https://qrco.de/bgXpKn----------Sponsor: FlexBeamFlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.Link: rechargehealthas.sjv.io/jRQyQ5----------In this week's Longevity News Roundup, Phil Newman and Nina Patrick examine mRNA plaque reversal, affordable longevity clinics, laser-driven skin rejuvenation, immune rejuvenation, cuffless blood pressure monitoring, and peptide evidence.Repair Biotechnologies received FDA pathway eligibility for its investigational mRNA therapy targeting intracellular cholesterol, a novel approach that aims to reverse arterial plaque rather than simply lower LDL or slow cardiovascular disease progression.Fountain Life launched a new $595 annual membership, signaling a strategic shift beyond luxury longevity medicine toward employer benefits, insurance integration, and broader access to advanced preventive care. Researchers from Nature’s Scientific Reports has found that Candela’s Nordlys fractional laser treatment produced sustained epigenetic changes associated with younger skin biology, raising the possibility that aesthetic procedures could influence the biology of aging rather than just appearance. United Therapeutics acquired Thymmune Therapeutics for $140 million, highlighting growing confidence in thymus regeneration, immune rejuvenation, and the commercial potential of therapies targeting age-related immune decline. Sky Labs presented its ring-type cuffless blood pressure monitor, CART BP pro, that has entered a large Korean cohort study, potentially making continuous cardiovascular monitoring more practical than traditional inflatable cuffs. Evipedia launched transparent, AI-supported evidence reviews covering 24 peptides, providing clinicians and consumers with an up-to-date resource as regulators continue scrutinizing peptide safety, efficacy, and clinical evidence.----------News & References:Repair Bio advances plaque regression program with FDA nod → https://longevity.technology/news/repair-bio-advances-plaque-regression-program-with-fda-nod/Fountain Life makes longevity accessible with $595 membership → https://longevity.technology/news/fountain-life-makes-longevity-accessible-with-595-membership/Laser treatment found to reverse skin aging markers → https://longevity.technology/news/laser-treatment-found-to-reverse-skin-aging-markers/United Therapeutics buys Thymmune Therapeutics for $140m → https://longevity.technology/news/united-therapeutics-buys-thymmune-therapeutics-for-140m/Evipedia expands evidence reviews to cover peptides → https://longevity.technology/news/evipedia-expands-evidence-reviews-to-cover-peptides/ Sky Labs’ blood pressure ring adopted for large-scale national health study → https://longevity.technology/news/sky-labs-blood-pressure-ring-adopted-for-large-scale-national-health-study/
• 
  This AI Can Detect Disease Before Symptoms 06.07.2026 1h 4min

  Hosts:Phil Newman: https://qrco.de/bgXpNYNina Patrick: ⁠⁠https://qrco.de/bgXpKn----------Sponsor: Viome Viome is a personalized health platform that uses RNA analysis and AI to provide insights into your microbiome, cellular health, and nutrition. By identifying what's happening inside your body in real time, Viome delivers tailored food, supplement, and lifestyle recommendations designed to support your long-term health and wellness journey.Click the link below to learn more.Link: viomehq.sjv.io/BX74XL----------Guests: Naveen JainFounder and CEO at Viome Life SciencesInstagram: www.instagram.com/naveenjainceo/?hl=enWebsite: www.viomelifesciences.com/----------What if the biggest breakthrough in longevity isn't changing your DNA, but understanding what your genes are doing right now?Phil Newman and Dr. Nina Patrick sit down with Naveen Jain, entrepreneur, innovator, and founder of Viome, to explore why RNA biology, AI, and the microbiome are reshaping the future of preventative healthcare. While DNA tells us what is possible, Jain argues that RNA reveals what is actually happening inside the body in real time, creating opportunities to detect dysfunction years before symptoms appear.From analyzing more than 400 quadrillion biological data points across 1.5 million biological samples to using AI to interpret millions of microbial and human gene expression signals, the conversation explores how precision diagnostics are moving beyond traditional blood testing. Jain explains why two people can eat the same foods and experience completely different biological outcomes, why there may be no such thing as a universally healthy food, and how personalized nutrition could become one of the most powerful tools for extending healthspan.The discussion also examines the rise of longevity medicine, the consumerization of healthcare, the growing role of AI in clinical decision making, and why early disease detection may become one of the defining advances of this decade. Jain shares how Viome is developing RNA-based diagnostics for conditions including oral cancer, pancreatic cancer, inflammatory bowel disease, and metabolic dysfunction, while also discussing the importance of scientific validation and evidence-based recommendations.In this episode, you’ll learn:How AI can interpret millions of biological signals that humans cannot analyze manually.Why personalized nutrition may outperform generalized dietary advice. How the microbiome influences inflammation, metabolism, cognition, and biological aging. Why foods like broccoli, spinach, avocado, almonds, and red meat can produce very different effects depending on your biology.How Viome's research is advancing early detection for pancreatic cancer, oral cancer, and metabolic disease.If you want to understand how AI, molecular biology, and the microbiome are changing the future of preventative medicine, this episode connects cutting-edge science with practical insights for extending healthspan and longevity.Subscribe for weekly episodes exploring longevity science, preventative medicine, and the innovations shaping how we live longer and better.
• 
  Why Klotho Is Becoming Longevity's Biggest Bet | Longevity News Roundup — Week 27, 2026 03.07.2026 26min

  Hosts:Phil Newman: https://qrco.de/bgXpNYNina Patrick: ⁠⁠https://qrco.de/bgXpKn----------Sponsor: FlexBeamFlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.Link: rechargehealthas.sjv.io/jRQyQ5----------In this week's Longevity News Roundup, Phil Newman and Nina Patrick examine CRISPR heart therapies, AI-guided Alzheimer's care, GLP-1 ecosystem expansion, biological age testing, Klotho programs, and regenerative medicine.Scribe Therapeutics secured more than $25 million from the California Institute for Regenerative Medicine (CIRM) to advance two CRISPR-based gene editing therapies toward human trials. The one-time treatments, STX-1200 and STX-1400, target inherited cardiovascular risk factors with the goal of durably reducing genetically driven heart disease risk.Eli Lilly's LillyDirect and ŌURA announced a collaboration to support people using prescribed GLP-1 therapies by combining access to treatment with wearable-based behavioral support. The initiative integrates sleep, activity, readiness, and other biometric insights to help reinforce healthy habits alongside obesity care, without sharing user data between the companies. NeuroXT and Beth Israel Deaconess Medical Center (BIDMC) expanded their collaboration to explore how AI could help identify the right treatment for the right Alzheimer’s patient. The research aims to identify which patients are most likely to benefit from emerging Alzheimer's therapies using imaging that is already widely available. Generation Lab launched SystemAge 2.1, describing it as the first biological age test to offer dedicated female and male versions. The platform analyzes more than 460 biomarkers across 21 organ systems from a needle-free blood sample, adding sex-specific assessments and organ-level tracking to monitor responses to longevity interventions. GARM Clinic debuted what it describes as the world's first Klotho Longevity Residency, a four-day educational program focused on Klotho-based gene therapy and regenerative medicine. Hosted in Roatán, Honduras, the residency brings together clinicians and researchers to explore translational longevity therapies in a more flexible regulatory setting. LyGenesis received a research award to expand its regenerative medicine platform into type 1 diabetes, to support a thymus program exploring immune tolerance to pancreatic islet transplantation. The funding will support preclinical development of a novel approach for tolerance induction following allogeneic pancreatic islet transplantation for type 1 diabetes, according to the company.----------News & References:Scribe lands $25m to advance heart disease gene therapies → https://longevity.technology/news/scribe-lands-25m-to-advance-heart-disease-gene-therapies/ŌURA-LillyDirect collab highlights new GLP-1 care model → https://longevity.technology/news/oura-lillydirect-collab-highlights-new-glp-1-care-model/AI and Alzheimer’s: NeuroXT, BIDMC aim to personalize care → https://longevity.technology/news/ai-and-alzheimers-neuroxt-bidmc-aim-to-personalize-care/Generation Lab launches SystemAge 2.1 as the first gender-specific biological age test → https://longevity.technology/news/generation-lab-launches-systemage-2-1-as-the-first-gender-specific-biological-age-test/GARM Clinic debuts world’s first Klotho longevity residency → https://longevity.technology/news/garm-clinic-debuts-worlds-first-klotho-longevity-residency/LyGenesis wins research award to advance type 1 diabetes cell therapy → https://longevity.technology/news/lygenesis-wins-research-award-to-advance-type-1-diabetes-cell-therapy/
• 
  The Longevity Discovery Hidden in Dolphins 29.06.2026 50min

  Hosts:Phil Newman: https://qrco.de/bgXpNYNina Patrick: ⁠⁠https://qrco.de/bgXpKn----------Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.Link: fatty15.com/UNLOCKED----------Guests: Stephanie Venn-Watson, DVM, MPHCo-Founder, Chief Executive Officer, Fatty15LinkedIn: www.linkedin.com/in/stephanievennwatson/Website: fatty15.com/Nicholas J. Schork, PhD, MACo-Founder, Senior Sciencist, Fatty15Research: www.researchgate.net/profile/Nicholas-SchorkWebsite: fatty15.com/----------What if one of the most influential nutrition recommendations of the last 50 years overlooked a nutrient essential for long-term health?Phil Newman and Dr. Nina Patrick sit down with Dr. Stephanie Venn-Watson, veterinary epidemiologist, public health scientist, inventor, and co-founder of Fatty15, alongside Dr. Nicholas Schork, distinguished professor and leading researcher in quantitative medicine and longevity science, to explore the emerging evidence behind C15 and the future of nutrition research.Together they examine how dietary guidelines introduced in 1977 led to widespread reductions in saturated fat consumption, while rates of obesity, metabolic disease, fatty liver disease, and type 2 diabetes continued to climb. Drawing on evidence from population studies, molecular biology, and animal research, they discuss why not all saturated fats behave the same way and how advances in metabolomics are helping researchers identify specific nutrients that may play critical roles in health and aging.The conversation traces the remarkable discovery of C15 from aging Navy dolphins, where researchers found that higher C15 levels were associated with healthier aging and lower rates of metabolic dysfunction. They explore why C15 is emerging as a candidate essential fatty acid, how it may support cell membrane stability, mitochondrial function, AMPK activation, inflammation regulation, and metabolic resilience, and why some researchers now view it as a promising geroprotector.They also discuss childhood nutrition, dairy consumption trends, grass-fed dairy, personalized versus essential nutrition, anemia, metabolic disease, and the challenges of translating emerging science into public health recommendations.In this episode, you’ll learn:Why researchers believe saturated fats should no longer be treated as a single categoryHow Navy dolphin research led to the discovery of C15's potential health benefitsWhy every 0.1% increase in circulating C15 has been associated with a 32% lower risk of developing type 2 diabetesWhat makes C15 a potential geroprotector that may influence multiple hallmarks of aging- How future dietary guidelines may evolve as evidence around C15 continues to growIf you want to understand how advances in nutrition science, aging biology, and public health research are reshaping our understanding of dietary fat, this episode offers a thought-provoking look at one of the most debated topics in longevity today.Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.
• 
  Are forever chemicals in your longevity stack? | Longevity News Roundup — Week 26, 2026 26.06.2026 28min

  Hosts:Phil Newman: https://qrco.de/bgXpNYNina Patrick: ⁠⁠https://qrco.de/bgXpKn----------Sponsor: FlexBeamFlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.Link: rechargehealthas.sjv.io/jRQyQ5----------In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine CRISPR gene editing, national longevity strategies, AI-powered drug discovery, next-generation health imaging, metabolic therapies, and the impact of forever chemicals on aging.Intellia Therapeutics reported positive Phase 3 results for lonvo-z, a one-time in vivo CRISPR treatment for hereditary angioedema. Patients saw an 87% reduction in monthly attacks, marking the first successful pivotal Phase 3 trial of an in vivo CRISPR gene-editing therapy.Canada's "Shaping Canada's Longevity Advantage" initiative, backed by Manulife and the World Economic Forum, aims to improve health, financial resilience, and social connectedness for one million Canadians within three to five years.Insilico Medicine signed a collaboration with SK Biopharmaceuticals worth more than $2.5 billion in potential milestone payments. The partnership will use Insilico's Pharma.AI platform to develop therapies for neuroimmune and central nervous system disorders.Midjourney unveiled plans for Midjourney Medical, a full-body imaging platform designed to create detailed body maps in approximately 60 seconds. The company plans to launch its first scanning facility in San Francisco in 2027.Cambrian Bio presented Phase 1B data for ATX-304 in adults with obesity and prediabetes. After eight weeks, participants showed an 8% increase in resting metabolic rate alongside reductions in visceral fat, liver fat, and triglycerides.New research linked common PFAS "forever chemicals" to accelerated epigenetic aging. The findings highlight how environmental exposures may influence biological age and why longevity strategies may need to address toxic burden alongside lifestyle interventions.----------News & References:World’s first in vivo gene editing Phase 3 win → https://longevity.technology/news/worlds-first-in-vivo-gene-editing-phase-3-win/Building Canada’s longevity advantage → https://longevity.technology/news/building-canadas-longevity-advantage/Insilico’s $2.5b AI drug discovery deal targets neuroimmune failure → https://longevity.technology/news/insilicos-2-5b-ai-drug-discovery-deal-targets-neuroimmune-failure/New image? AI art giant Midjourney’s wildest leap into longevity → https://longevity.technology/news/new-image-ai-art-giant-midjourneys-wildest-leap-into-longevity/Human data validate Cambrian Bio’s aging target → https://longevity.technology/news/human-data-validate-cambrian-bios-aging-target/Forever chemicals may be aging you – longevity needs to wake up → https://longevity.technology/news/forever-chemicals-may-be-aging-you-longevity-needs-to-wake-up/
• 
  This AI Could Predict Disease Decades Early | Dr. Wei-Wu He on Genomics & Longevity 22.06.2026 1h

  Hosts:Phil Newman: https://qrco.de/bgXpNYNina Patrick: ⁠⁠https://qrco.de/bgXpKn----------Sponsor: FlexBeamFlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.Link: rechargehealthas.sjv.io/jRQyQ5----------Guest: Wei-Wu HeChairman and CEO, Human Longevity, Inc.LinkedIn: www.linkedin.com/in/wei-wu-he-ph-d-he-him-b6957313/Website: www.humanlongevity.com/----------What if the future of medicine isn't about treating disease, but predicting it years before symptoms ever appear?Phil Newman and Dr. Nina Patrick sit down with Dr. Wei-Wu He, CEO and Executive Chairman of Human Longevity Inc. (HLI), to explore how genomics, AI, multiomics, and precision medicine are converging to create an entirely new model of healthcare. A longtime entrepreneur, investor, and advocate for longevity science, Wei-Wu shares how HLI has evolved from one of the world's most ambitious genomics projects into a global precision health platform focused on disease prevention, risk prediction, and personalized intervention.The conversation explores why genome sequencing may become one of the most important medical tools of the next decade, and why Dr. He believes every person should have access to their genomic data. He explains how advances in AI are making it possible to interpret vast amounts of biological information, turning genome sequences, imaging scans, blood biomarkers, and longitudinal health records into actionable insights that can guide both patients and physicians.Wei-Wu also discusses HLI's collaboration with Insilico Medicine to build AI-powered foundation models for longevity and disease prediction, the importance of diverse global datasets, and why population-specific genomic algorithms may outperform one-size-fits-all approaches developed from Western biobanks alone.The discussion expands beyond technology to explore the broader future of healthcare. Why are countries like China, the UAE, and Singapore moving aggressively into genomic medicine? What role will governments, insurers, and healthcare systems play in making prevention more accessible? And how close are we to a world where AI-powered health guidance becomes a routine part of everyday medical care?In this episode, you’ll learn:Why recent research suggests genetics may account for roughly 50% of lifespan variationHow whole genome sequencing is becoming dramatically more affordable and accessibleWhy AI may outperform human experts in specific diagnostic tasksWhy pancreatic cancer outcomes depend heavily on stage-zero and stage-one detectionWhy China, the UAE, and other countries are investing heavily in genomic healthcareHow longevity clinics may evolve into mainstream healthcare over the coming decadeIf you want to understand how AI, genomics, and longitudinal health data may transform medicine, this episode connects cutting-edge science with practical strategies for extending healthspan.Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.
• 
  The Rise of Preventive Longevity Medicine | Longevity News Roundup — Week 25, 2026 19.06.2026 27min

  Hosts:Phil Newman: https://qrco.de/bgXpNYNina Patrick: ⁠⁠https://qrco.de/bgXpKn----------Sponsor: FlexBeamFlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.Link: rechargehealthas.sjv.io/jRQyQ5----------In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine GLP-1 off-ramps, ovarian aging, combination longevity therapies, AI-driven aging models, Alzheimer’s prevention, and regenerative stem cell advances.Fractyl Health released one-year data from its REVEAL-1 study, showing patients maintained roughly 78% of their GLP-1-related weight loss after receiving the Revita procedure. The results raise the possibility of a long-term off-ramp for Ozempic and similar drugs, though controlled trials are still needed.The Longevity Science Foundation launched a campaign to accelerate ovarian aging research, an area many experts consider critically underfunded despite its relevance to female healthspan and aging biology.Immorta Bio published peer-reviewed preclinical findings showing more than a 70% lifespan increase when senescent cell clearance was combined with regenerative therapies, supporting the idea that multiple aging mechanisms may need to be addressed simultaneously.Gero secured $17 million in new funding and expanded its collaboration with Chugai Pharmaceutical, applying physics-based models and large-scale human datasets to identify aging-related therapeutic targets.Eli Lilly signed a deal potentially worth more than $1 billion with AlzeCure Pharma to develop a preventive Alzheimer's therapy aimed at stopping disease processes years before symptoms emerge.MuseCell Innovations continues advancing stress-resistant stem cell therapies designed to repair damaged tissue while potentially opening new pathways for regenerative longevity medicine.----------News & References:A new off-ramp from Ozempic and Wegovy? → https://longevity.technology/news/a-new-off-ramp-from-ozempic-and-wegovy/Can crowdfunding change ovarian aging research (and opinions)? → https://longevity.technology/news/can-crowdfunding-change-ovarian-aging-research-and-opinions/Dual stem cell and anti-aging therapy extends mouse lifespan by over 70% → https://longevity.technology/news/dual-stem-cell-and-anti-aging-therapy-extends-mouse-lifespan-by-over-70/Gero raises $17m to model the mathematics of aging → https://longevity.technology/news/gero-raises-17m-to-model-the-mathematics-of-aging/Lilly places $1b bet on AlzeCure’s Alzheimer’s project → https://longevity.technology/news/lilly-places-1b-bet-on-alzecures-alzheimers-project/Harnessing Muse cells in longevity medicine → https://longevity.technology/news/harnessing-muse-cells-in-longevity-medicine/
• 
  The Drugs That Could Slow Aging Are Already Here | Dr. Nir Barzilai 15.06.2026 1h

  Hosts:Phil Newman: https://qrco.de/bgXpNYNina Patrick: ⁠⁠https://qrco.de/bgXpKn----------Sponsor: FlexBeamFlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.Link: rechargehealthas.sjv.io/jRQyQ5----------Guests: Nir BarzilaiDirector of the Institute for Aging Research at the Albert Einstein College of MedicineLinkedIn: www.linkedin.com/in/nir-barzilai-7a86a7212/Link to Nir's works: einsteinmed.edu/faculty/484/nir-barzilai, www.sciencedirect.com/author/7005711408/nir-barzilai----------What if aging itself is the biggest medical opportunity of the 21st century?Phil Newman and Dr. Nina Patrick sit down with Dr. Nir Barzilai, physician-scientist, professor of medicine and genetics, founding director of the Institute for Aging Research at Albert Einstein College of Medicine, and one of the pioneers of geroscience, to explore why targeting the biology of aging could delay multiple diseases at once.Together they explain how decades of centenarian research revealed that healthy longevity is biologically achievable. From centenarians who remain healthy until their final year of life to real-world evidence showing GLP-1 therapies can reduce hospitalization and mortality, these insights are reshaping modern medicine. They also discuss metformin, SGLT2 inhibitors, biological age testing, longevity biomarkers, regulatory progress at the FDA, and the future of aging therapeutics.Barzilai shares the scientific foundations behind the geroscience hypothesis, the idea that aging itself is the major driver of chronic disease. He explains why interventions that target aging biology may offer broader benefits than treating diseases one by one, and how decades of research have shifted the conversation from lifespan extension toward extending healthspan and compressing morbidity.The discussion also explores the challenges facing the longevity field, from supplement overuse and biomarker validation to clinical trial design and regulatory pathways. Barzilai offers his perspective on emerging therapies, the promise of biological age measurement, and why the next generation of longevity medicine may look very different from today's healthcare model.In this episode, you’ll learn:Why aging biology drives diseases like Alzheimer's, diabetes, and cardiovascular diseaseHow centenarians compress morbidity and remain healthy into extreme old ageWhy GLP-1 therapies reduced hospitalization and death by roughly 60% in one studyWhy Barzilai tracks proteomics and believes biomarkers will transform longevity medicineWhich longevity interventions he personally uses, including metformin and RejuvantIf you want to understand how aging science is moving from theory to clinical reality, this episode connects cutting-edge research with practical insights for extending human healthspan.Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.
• 
  Can Wearables Become Clinical Tools? | Longevity News Roundup — Week 24, 2026 12.06.2026 30min

  Hosts:Phil Newman: https://qrco.de/bgXpNYNina Patrick: ⁠⁠https://qrco.de/bgXpKn----------Sponsor: Fatty15Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.Link: https://partners.fatty15.com/UNLOCKED----------In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine clinical AI, cortisol wearables, blood pressure monitoring, animal longevity biotech, stem cell therapies and next-generation obesity treatments.Longevitix launched a clinical intelligence platform designed for longevity, preventive and functional medicine clinics. The system combines laboratory results, wearable data, clinical notes and patient histories into physician-ready summaries, prioritized insights and personalized intervention plans.Rejuvenate Bio secured $6 million in new financing alongside a strategic collaboration with Merck Animal Health. The partnership aims to advance gene therapies for chronic and age-related conditions in pets, highlighting growing interest in animal longevity as a pathway for translational research.Adaptyx Biosciences presented data on a wearable cortisol sensor capable of continuously tracking free cortisol over multiple days. The device successfully captured daily cortisol rhythms and showed strong agreement with paired blood measurements.Celularity partnered with Fountain Life to offer placental-derived cell therapies at Fountain Life’s Florida facility. The collaboration leverages Florida’s evolving framework for early-stage stem cell treatments and could provide valuable real-world clinical data.South Korea became the first country to include Skylabs’ Cart BP Pro in its national hypertension treatment guidelines. The ring-shaped device continuously monitors blood pressure without the need for a traditional arm cuff, helping detect risks that often go unnoticed during routine clinic visits.MitoRx presented preclinical data for MTRX31, a mitochondrial-targeted obesity therapy designed to improve metabolic health through a mechanism distinct from GLP-1 drugs. The approach could serve as either a standalone treatment or a complementary therapy, making it a potentially attractive target for future pharmaceutical partnerships.----------News & References:Longevitix launches AI platform to tackle longevity data overload → https://longevity.technology/news/longevitix-launches-ai-platform-to-tackle-longevity-data-overload/Rejuvenate Bio secures funding and Merck partnership → https://longevity.technology/news/rejuvenate-bio-secures-funding-and-merck-partnership/Adaptyx debuts first continuous cortisol tracking wearable → https://longevity.technology/news/adaptyx-debuts-first-continuous-cortisol-tracking-wearable/Celularity, Fountain Life to offer experimental cell therapy in Florida → https://longevity.technology/news/celularity-fountain-life-to-offer-experimental-cell-therapy-in-florida/Goodbye, arm cuffs? South Korea bets on ring-type BP monitor → https://longevity.technology/news/goodbye-arm-cuffs-south-korea-bets-on-ring-type-bp-monitor/MitoRX’s new obesity drug targets metabolism, not appetite → https://longevity.technology/news/mitorxs-new-obesity-drug-targets-metabolism-not-appetite/
• 
  Could Banking Your Cells Today Add Healthy Years Tomorrow? 08.06.2026 47min

  Hosts:Phil Newman: https://qrco.de/bgXpNYNina Patrick: ⁠⁠https://qrco.de/bgXpKn----------Sponsor: Acorn BiolabsAcorn Biolabs is a science-driven regenerative medicine company that preserves your own hair follicle stem cells for future personalized treatments. Through a simple, non-invasive collection process, Acorn helps you bank your healthiest cells today, supporting regenerative skincare and hair therapies now while preparing for the future of longevity and cellular medicine.Click the link below to learn more about Acorn's innovative approach to stem cell preservation.Link: www.acorn.me ----------Guests: Drew TaylorCEO and co-founder of Acorn BiolabsLinkedIn: https://www.linkedin.com/in/drew-taylor-65b6ab10/Website: www.acorn.me ----------What if the smartest longevity investment isn’t another supplement or infusion, but preserving your younger cells before aging changes them?Phil Newman and Dr. Nina Patrick sit down with Drew Taylor, CEO and co-founder of Acorn Biolabs and biomedical engineer, to explore how regenerative medicine is shifting from reactive repair toward biological preservation and future optionality.Together they explain why hair follicle stem cells may offer one of the most accessible entry points into autologous regenerative medicine. From collecting stem cells with simple hair plucking instead of invasive bone marrow extraction to cryopreserving younger biology for decades, Drew breaks down how Acorn’s platform aims to freeze cellular aging in time. The conversation also explores how these cells produce secretomes rich in growth factors, cytokines, collagen, extracellular vesicles, and exosomes that can later be used in skin rejuvenation, hair restoration, and orthopedic applications.The discussion also dives into the darker side of the industry, including stem cell tourism, regulatory gaps, misinformation, and the risks patients face when traveling abroad for unverified treatments. Drew argues that ethical regenerative medicine must prioritize transparency, patient safety, and clinically validated protocols over hype.They also explore the future of the field, including NK cells engineered from preserved hair follicle cells, cartilage regeneration research, AI-powered omics analysis, fertility applications, Parkinson’s research, and the possibility of one day growing replacement tissues and organs from your own preserved biology.In this episode, you’ll learn:Why Acorn can generate up to 108 treatment vials from one collectionHow secretomes deliver growth factors, cytokines, collagen, and exosomesWhy stem cell numbers decline faster than stem cell performance with ageHow NK cells derived from hair follicles suppressed cancer cell growth in lab studiesWhy Drew believes “cells will become the next currency in healthcare”If you want to understand how regenerative medicine could shift from aesthetics to personalized disease prevention, this episode connects cutting-edge cell science with practical longevity strategies.Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.
• 
  Are Brain Interfaces Finally Ready For Daily Life? | Longevity News Roundup — Week 23, 2026 05.06.2026 22min

  Hosts:Phil Newman: https://qrco.de/bgXpNYNina Patrick: ⁠⁠https://qrco.de/bgXpKn----------Sponsor: Fatty15Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.Link: partners.fatty15.com/UNLOCKED----------In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine wearable health innovation, brain-computer interfaces, physician-led longevity care, Alzheimer’s research, and the evolution of the longevity industry.ŌURA launched Ring 5, a redesigned device that is 40% smaller while maintaining week-long battery life. New features include blood pressure signals, breathing monitoring, GLP-1 insights, and integrated health data designed to make wearables a central health management platform.Ability Neurotech received approval in the Netherlands to begin long-term studies of its battery-free optical brain implant in ALS patients. The system is designed for everyday home use, highlighting the industry's shift from laboratory demonstrations toward real-world functionality.Elysium Health launched The Elysium Longevity Institute (TELI), combining physician oversight, advanced testing, supplements, prescriptions, and peptides. The move reflects a broader trend of established longevity brands expanding into comprehensive clinical care.A study of 69 women aged 65 and older linked poor sleep, increased Alzheimer’s genetic risk, greater tau accumulation, and weaker visual memory. Researchers suggest sleep and visual memory changes may offer valuable signals of early disease processes.From 95 startups across 32 countries entering the Longevity Show pitch competition to growing investment in diagnostics, prevention platforms, AI, and care delivery, the sector is increasingly focused on translating science into scalable healthspan solutions.The broader transition from sick care to prevention-led systems, where aging biology becomes a core risk factor and healthspan metrics replace disease counting. Insurance, pensions, and healthcare payment models need to adapt as longevity becomes embedded in economic infrastructure, not just products.----------News & References:What poor sleep may be telling women about Alzheimer’s? → https://longevity.technology/news/what-poor-sleep-may-be-telling-women-about-alzheimers/Five finalists advance in longevity pitch contest → https://longevity.technology/news/five-finalists-advance-in-longevity-pitch-contest/ŌURA’s smallest smart ring launched with expanded health monitoring → https://longevity.technology/news/ouras-smallest-smart-ring-launched-with-expanded-health-monitoring/Optical brain implant moves into real-world use → https://longevity.technology/news/optical-brain-implant-moves-into-real-world-use/Elysium expands into physician-led longevity care → https://longevity.technology/news/elysium-expands-into-physician-led-longevity-care/Public health faces longevity imperative → https://longevity.technology/news/public-health-faces-longevity-imperative/
• 
  Dezawa MuseCells® Explained: The Next Generation of Regenerative Medicine? 01.06.2026 52min

  Hosts:Phil Newman: https://qrco.de/bgXpNYNina Patrick: ⁠⁠https://qrco.de/bgXpKn----------Sponsor: MuseCell InnovationsMuseCell Innovations is a science-backed regenerative medicine company developing patented Dezawa MuseCells®, unique stem cells that support the body's natural repair and regeneration processes. Benefits include cellular renewal, tissue repair, healthy aging, improved resilience, and overall wellbeing.Click the link below to explore the science, research, and technology behind this innovative approach to regenerative medicine.Link: musecellinnovations.com----------Guests: Dominik Duscher MD PhDPresident & Chief Executive Officer at MuseCell InnovationsInstagram: www.instagram.com/dr.dominikduscher/Website: musecellinnovations.comDr. Jeffrey J. WiegersChief Medical Officer at MuseCell InnovationsInstagram: www.instagram.com/jeffwiegersWebsite: musecellinnovations.com----------What if a naturally occurring stem cell subpopulation could home to sites of injury and support tissue repair across multiple indications?Phil Newman and Dr. Nina Patrick sit down with Dr. Dominik Duscher, MD PhD, President and CEO of MuseCell Innovations, and Dr. Jeffrey Wiegers, MD, Chief Medical Officer, to explore the unique properties of Dezawa MuseCells®. In this session, they describe these cells as highly enriched in a purified product with pluripotent-like potential, signaling that enables targeted homing, and immune tolerance that supports allogeneic use without major immune activation, based on early human experience.From first-in-human intravenous use in acute myocardial infarction showing safety and encouraging left ventricle performance signals, to randomized placebo-controlled subacute ischemic stroke data showing higher response rates than placebo, they walk through human trial experience without overstating effects. They also discuss repeated intravenous dosing in an amyotrophic lateral sclerosis study suggesting stabilizing signal with minimal adverse events, single-arm spinal cord injury data, and early work in neonatal hypoxic-ischemic encephalopathy showing recovery signals in some infants.They also address broader practicalities around manufacturing rigor, quality control, and provider competency as determinants of safety in clinical settings, and they describe the need for clear documentation and oversight to avoid unlicensed or inferior products.In this episode, you’ll learn:Why pluripotency, homing ability, and immune tolerance are considered key features of Dezawa MuseCells® and how these properties may relate to tissue repair. What early human studies in conditions like heart attack, stroke, ALS, spinal cord injury, and neonatal brain injury have shown in terms of safety and early clinical signals.Why manufacturing quality, purification, and standardization are critical for consistency and safety in cell-based therapies.Why clinician expertise and proper oversight matter when these therapies move from research into clinical use. How to think about verifying product authenticity and avoiding unregulated or non-standard cell therapies.If you want to understand the biological features, emerging human data, and practical considerations around Dezawa MuseCells® as discussed by leaders in the field, this episode connects cellular biology with real-world context for regenerative medicine and longevity. Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.
• 
  Sam Altman's $1.8B Longevity Company, CRISPR & AI Health | Longevity News Roundup — Week 22, 2026 29.05.2026 23min

  Hosts:Phil Newman: https://qrco.de/bgXpNYNina Patrick: ⁠⁠https://qrco.de/bgXpKn----------Sponsor: Fatty15Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.Link: https://partners.fatty15.com/UNLOCKED----------In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine FDA-cleared sleep diagnostics, safer CRISPR therapies, longevity clinic accountability, Retro Biosciences’ valuation, and AI-driven preventative healthcare.Sunrise received FDA clearance for Sunrise Air, a rechargeable at-home sleep apnea diagnostic using a chin sensor for multi-night testing. The device tracks airflow, oxygen, pulse, and snoring while targeting underdiagnosis linked to cardiovascular and cognitive decline.Insilico and Human Longevity have announced a multimillion-dollar collaboration to build what they describe as the industry’s first large-scale AI foundation model dedicated to longevity science. Daewoong Pharmaceutical acquired Turn Biotechnologies’ partial reprogramming assets, including its ERA mRNA platform. The deal gives longevity-focused age reversal IP a new clinical and regulatory pathway.Scribe Therapeutics presented preclinical ELXR CRISPR data showing 18-month cholesterol reduction in primates through epigenetic PCSK9 silencing. The platform reduced off-target activity by up to 100-fold without permanently altering DNA.At the Milan Longevity Summit 2026 they explored how longevity clinics are moving from wellness branding toward evidence-based preventative medicine. Clinics are increasingly being pressured to prove outcomes through validated biomarkers and longitudinal patient data.Retro Biosciences reached a $1.8 billion valuation while advancing an Alzheimer’s drug into human trials. Retro’s approach focuses on boosting a natural cellular process called autophagy, essentially the body’s built-in recycling program.----------News & References:Retro Bio’s $1.8b moment: Hopes up as Alzheimer’s trial advances → https://longevity.technology/news/retro-bios-1-8b-moment-hopes-up-as-alzheimers-trial-advances/Longevity clinics face their proving ground → https://longevity.technology/news/longevity-clinics-face-their-proving-ground/Sunrise receives FDA clearance for rechargeable at-home sleep test → https://longevity.technology/news/sunrise-receives-fda-clearance-for-rechargeable-at-home-sleep-test/Daewoong acquires Turn Bio age-reversal assets → https://longevity.technology/news/daewoong-acquires-turn-bio-age-reversal-assets/Scribe Therapeutics debuts CRISPR platforms for cholesterol treatment → https://longevity.technology/news/scribe-therapeutics-debuts-crispr-platforms-for-cholesterol-treatment/Insilico and Human Longevity eye to predict disease early with AI → https://longevity.technology/news/insilico-and-human-longevity-eye-to-predict-disease-early-with-ai/
• 
  This Wearable Tracks the Female Cycle in Real Time 25.05.2026 30min

  Hosts:Phil Newman: https://qrco.de/bgXpNYNina Patrick: ⁠⁠https://qrco.de/bgXpKn----------Sponsor: Fatty15 Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.Link: fatty15.com/UNLOCKED----------Guests: Jenny DuanCo-Founder and CEO of Clair HealthLinkedIn: https://www.linkedin.com/in/jennysduan/Website: https://wearclair.com/Abhinav AgarwalCo-Founder and CTO of Clair HealthLinkedIn: https://www.linkedin.com/in/agarwalaabhinav/Website: https://wearclair.com/----------What if women’s hormones were tracked like heart rate, continuously and contextually, not through annual snapshots?Phil Newman and Dr. Nina Patrick sit down with Jenny Duan, CEO of Clair, and Abhinav Argawal, CTO, to explore how a jewelry-inspired wrist wearable uses multi-sensor biosignals to infer estrogen and progesterone in real time across daily life.They explain how signals such as skin temperature, HRV, sweat response, intracellular and extracellular current shifts, and more than 100 derived biomarkers are combined through sensor fusion to model hormone trajectories that update throughout the day. From forecasting an athlete’s rate of perceived exertion days before training to identifying progesterone patterns associated with PCOS and endometriosis risk, these examples show what continuous data reveals that snapshot testing cannot. The discussion also uncovers how this level of visibility allows the female cycle to be understood as nine distinct sub-phases rather than the traditional four.They also discuss how lifestyle context, such as sleep, hydration, stress, and schedule, is integrated into the model to avoid contradictions between device feedback and lived experience. Early beta studies across PCOS, endometriosis, and perimenopause cohorts are already informing how this data can support fertility planning and symptom awareness.In this episode, you’ll learn:Why the female cycle can be divided into nine hormone sub-phasesHow 230 biomarkers are refined into 100 inputs for hormone modelingHow athletes can adjust hydration and nutrition before exertion spikesHow progesterone trends may signal risk patterns for PCOS and endometriosisWhy fertility and perimenopause represent 60% of early pre-ordersIf you want to understand how continuous hormone visibility reshapes female health decisions across life stages, this episode connects biosensing, AI modeling, and practical insights for longevity. Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.
• 
  GLP‑1 Gene Therapy: A One‑Time Fix for Obesity & Diabetes? | Longevity News Roundup — Week 21, 2026 22.05.2026 23min

  Hosts:Phil Newman: https://qrco.de/bgXpNYNina Patrick: ⁠⁠https://qrco.de/bgXpKn----------Sponsor: Fatty15Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.Link: https://partners.fatty15.com/UNLOCKED----------In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick examine pancreatic cancer immunotherapy, GLP-1 gene therapy, immune system rebuilding, cardiovascular plaque reversal and microbiome medicine.MatterBio filed its first IND application for Lm-LLO-TT, an engineered Listeria-based therapy targeting pancreatic ductal adenocarcinoma. Pending FDA clearance, the company plans a Phase 1/2a study evaluating safety, dosing and early efficacy in advanced pancreatic cancer patients resistant to conventional immunotherapy.Fractyl Health received European approval to begin a first-in-human Phase 1/2 trial of RJVA-001, GLP-1 gene therapy for obesity and type 2 diabetes. The therapy uses endoscopic ultrasound-guided pancreatic delivery to program beta cells to produce GLP-1 in response to meals rather than relying on repeated injections.Ossium Health presented clinical trial data showing successful engraftment using cryopreserved bone marrow collected from deceased organ donors. Researchers believe the banking platform could eventually simplify bone marrow transplantation logistics and expand future immune system renewal applications.Cyclarity shared new progress on therapies targeting 7-ketocholesterol, an oxidized cholesterol molecule linked to plaque instability and chronic arterial inflammation. Rather than slowing plaque growth, the company aims to physically remove toxic cholesterol deposits already embedded within blood vessel walls.Microbiotica reported positive Phase 1b MELODY-1 trial data for MB097, a microbiome therapy containing nine bacterial strains combined with KEYTRUDA in advanced melanoma patients. The therapy showed successful gut engraftment and encouraging signals that microbiome modulation may help overcome immunotherapy resistance.The episode also explored health equity in longevity medicine with Poonam Desai ahead of The Longevity Show. Discussions focused on sex-specific medicine, unequal access to longevity care and the risks of building precision health systems around biased clinical data.----------News & References:‘Rebuilding the human immune system is possible’ → https://longevity.technology/news/rebuilding-the-human-immune-system-is-possible/Fractyl Health to begin EU trials for one-time weight loss gene therapy → https://longevity.technology/news/fractyl-health-to-begin-eu-trials-for-one-time-weight-loss-gene-therapy/Matter Bio takes pancreatic therapy to clinic → https://longevity.technology/news/matter-bio-takes-pancreatic-therapy-to-clinic/New data suggests plaque damage can be cleared → https://longevity.technology/news/new-data-suggests-plaque-damage-can-be-cleared/Microbiome medicine moves past wellness into clinics → https://longevity.technology/news/microbiome-medicine-moves-past-wellness-into-clinics/‘Equity in longevity is the entire ballgame’ → https://longevity.technology/news/equity-in-longevity-is-the-entire-ballgame/